A Phase 2/3 interventional study of ICP-332 Tablets and ICP-332 placebo Tablets in Chronic Spontaneous Urticaria (CSU), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 30 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.
Among the 34 studies in Chronic Urticaria with a site in China, this one is the 7th largest by planned enrollment of the 30 interventional ones that give a count, is one of 11 that started in 2026, is one of 2 in phase 2/3, reaches primary completion later than 19 of the 19 other live ones, and was the 23rd registered.
197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.
Browse Chronic Urticaria studies →16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:
Novelty Nobility, Inc. · Sites in China
Ages 18–75 · Healthy volunteers
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Yuhan Corporation · Sites in China, Bulgaria, Poland and 1 more country
Ages 18–75
Jemincare · Sites in China
Ages 18+
Keymed Biosciences Co.Ltd · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 10
First in 2013; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 344 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 110 across the 30 interventional studies, 270 across the 4 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 34 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing InnoCare Pharma Tech Co., Ltd., one of the names counted as InnoCare Pharma Limited. Under that name alone:
Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.
InnoCare Pharma Limited has 1 study filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
10 of the studies in Chronic Urticaria with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07402213Phase 3JemincareTrial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. | 2027-06-07 |
| NCT06604949Longbio PharmaA Study of Single Dose of LP-003 in Healthy Adult Subjects | 2026-11 |
| NCT07005713BeOne MedicinesA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants | 2026-11-30 |
| NCT07613866Chengdu Suncadia Medicine Co., Ltd.A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria | 2026-12 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
Add all 10 to your calendar (.ics) → With an account.
Among the 34 studies in Chronic Urticaria with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ICP-332 will be administered as tablet
Drug: ICP-332 Tablets
ICP-332 will be administered as tablet
Drug: ICP-332 Tablets
ICP-332 will be administered as tablet
Drug: ICP-332 Tablets
ICP-332 Placebo will be administered as tablet
Drug: ICP-332 placebo Tablets
ICP-332 will be administered as tablet
Drug: ICP-332 Tablets
ICP-332 Placebo will be administered as tablet
Drug: ICP-332 placebo Tablets
ICP-332 will be administered as tablet for 12 weeks
ICP-332 placebo will be administered as tablet for 12 weeks
ICP-332 will be administered as tablet for 24 weeks
Phase 2: Change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4.
The Weekly Urticaria Activity Score (UAS7) is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42 (highest urticaria severity), and a minimum possible score of 0.
Time frame: 4 weeks
Phase 3: Change from baseline in UAS7 at Week 12.
The Weekly Urticaria Activity Score (UAS7) is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The possible range of the UAS7 score is 0 - 42 (highest hives and itch severity).
Time frame: 12 weeks
Started Feb 2026 (actual). Primary completion is estimated for Sep 2028, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ICP-332
Beijing InnoCare Pharma Tech Co., Ltd. →